Clinical Trial Update: HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating reduced-dose post-transplant cyclophosphamide as GVHD prophylaxis in HLA-mismatched unrelated donor peripheral blood stem cell…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Chronic Lymphocytic Leukemia
• Chronic Myeloid Leukemia
• Lymphoma
• Myelodysplastic Syndromes
• Myelofibrosis
• Myelomonocytic Leukemia

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)

Snippet

Sponsor: Center for International Blood and Marrow Transplant Research | Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 | Status: ACTIVE_NOT_RECRUITING